Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.24), $0.01 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $30.54 million versus the consensus estimate of $38.2 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2025 revenue of $140-155 million, versus the consensus of $165.5 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.